Screening for ASXL1 and SRSF2 Mutations Is Imperative for Treatment Decision-Making in Otherwise Low or Intermediate-1 Risk Patients With Myelofibrosis

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15010
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients With Intermediate and High-Risk Myelofibrosis

Clinical Cancer Research
Cancer ResearchOncology
2012English

ASXL1 Mutations in Chinese Patients With Essential Thrombocythemia

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2018English

SRSF2 Mutations in Primary Myelofibrosis: Significant Clustering With IDH Mutations and Independent Association With Inferior Overall and Leukemia-Free Survival

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Low-Dose Rate Brachytherapy for Patients With Low- Or Intermediate-Risk Prostate Cancer: A Systematic Review

Canadian Urological Association Journal
Urology
2013English

Screening for Chlamydia Trachomatis in Low-Risk Obstetric Patients

Infectious Diseases in Obstetrics and Gynecology
DermatologyGynecologyInfectious DiseasesObstetrics
1994English

Decision Aids for People Facing Health Treatment or Screening Decisions

2011English

Shared Decision Making Emphasized for Prostate Screening

Cancer Discovery
Oncology
2018English

Therapeutic Decision-Making for Patients With Fluctuating Mitral Regurgitation

Nature Reviews Cardiology
Cardiovascular MedicineCardiology
2015English

The Paucity of Evidence Supporting Screening for Stages 1-3 CKD in Asymptomatic Patients With or Without Risk Factors

Clinical Journal of the American Society of Nephrology
EpidemiologyNephrologyCritical CareTransplantationIntensive Care Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy